CD274 and hepatocellular carcinoma: Given its unique properties as a PD-L1 mAb, there are several ongoing clinical trials investigating the future role of avelumab in the therapy of CRC (NCT05291156, NCT05289856, NCT04513951, NCT03563157), HCC (NCT05249569), and ICC (NCT04708067, NCT04068194).